ASH 2021 | An analysis of survival outcomes in patients with triple-class refractory myeloma
In this video, Susan Bal, MD, UAB School of Medicine, Birmingham, AL, explains some results from a study which used the MAMMOTH dataset (NCT01985126) to analyze patients with multiple myeloma (MM) who are refractory to CD38-targeted monoclonal antibodies, and evaluated them until they became triple-class refractory. Dr Bal first discusses how this study allowed researchers to understand the outcomes of MM patients prior to the availability of novel agents such as selinexor, melflufen, and belantamab mafodotin. Dr Bal then highlights the results from this study, comparing progression-free survival (PFS) and overall survival (OS) in patients who were triple-class refractory, penta-exposed and/ or penta-refractory, and how outcomes differed among the patient groups. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
